Panel Discussion: Now We Have Successfully Targeted RAS G12C, What’s Next?
Time: 5:00 pm
day: Day Two
As we close out two days dedicated to critical updates and project successes from across this community, this panel will dive into a discussion considering what is next for therapeutics targeting RAS-mutant cancers. After 40 years of dedicated science and significant progress, it is critical we expand the landscape of RAS targeted therapies beyond G12C and consider where this hugely promising therapeutic can see its next success